GE HealthCare Technologies Inc. (GEHC)
Health Care · Health Care Equipment · US stock · S&P 500 component
$69.57
▼ -0.78 (1.11%)
Fair valueUndervalued
$105 +50.9% to fair value
$52fair band $73–$136$157
Day's range
$69.45 – $71.32
52-week range
$58.72 – $89.64
About GE HealthCare Technologies Inc.
Hospitals and clinics use medical imaging machines, patient monitoring equipment and diagnostic agents from GE HealthCare. Its products include MRI, CT, X-ray and ultrasound systems, along with contrast agents, radiopharmaceuticals, and digital software and services that help clinicians interpret images and manage care. The company was separated from General Electric and is organised into imaging, advanced visualisation, patient care and pharmaceutical diagnostics businesses.
Revenue comes from equipment, from service contracts that support installed machines, and from recurring supplies such as contrast agents. Sales were $21.0 billion over the last twelve months, rising 4.0% a year over the last three years. The operating margin is 12.6%, and the business earns a profit of 11% on the capital invested in it. Net debt is 3.1 times EBITDA. It pays a dividend with a yield of 0.2%. On the site's X-Ray Score it receives 49 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $58.72 – $89.64Volume 3,115,400Daily, split-adjusted
Vitals
Market cap$31.8B
52-week range$58.72 – $89.64
Volume (last day)3,115,400
P/E (TTM)16.7
EBIT / EV yield6.6%
Free-cash-flow yield–
Dividend yield0.2%
Revenue (TTM)$21.0B
Net income (TTM)$1.9B
Operating margin12.6%
Return on capital10.7%
Debt incl. leases$10.5B
Cash & securities$2.3B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$105model spread $101 – $109
Undervalued
+50.9% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $70
Undervalued < $73Fair $73 – $136Overvalued > $136
10-year DCF (market-scaled)
$75
Peer multiples
$118
Earnings power floor (not blended)
$39
Fundamentals-adjusted multiple
$122
Growth the price implies
9.0%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, but the price is low
Our models put fair value above today's price, but models can be wrong, so check the business first. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
84/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield6.6%
Fair value vs price1.5×
Growth
Weak
38/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)4.0%
EPS growth (3y)2.5%
Growth consistency90%
Profitability
Weak
46/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital10.7%
Operating margin12.6%
Gross profitability22.1%
Financial health
Weak
38/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA3.1×
Interest coverNo interest cost
Dividends
Weak
17/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.2%
Quarterly results: last 6 quarters
+2.2%
Dec '24
+2.7%
Mar '25
+3.5%
Jun '25
+5.8%
Sep '25
+7.1%
Dec '25
+7.4%
Mar '26
Revenue against the same quarter a year earlier. Latest quarter revenue $5.1B, diluted EPS $0.85.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 3 Good · ● 5 Average · ● 5 BadCash quality
Risk models
Altman Z''Bad
Piotroski F-ScoreBad
Growth
EPS growth (3y)Average
Revenue growth (3y)Average
Growth consistencyAverage
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverGood
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginAverage
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 48/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B |
| Operating income | $2.8B | $2.5B | $2.4B | $2.6B | $2.8B |
| Net income | $2.2B | $1.9B | $1.6B | $2.0B | $2.1B |
| Operating cash flow | – | – | – | – | – |
| Operating margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% |
| Free cash flow | – | – | – | – | – |
| Diluted EPS | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
11 bullish · 3 neutral · 2 bearish
Weekly
Neutral
5 bullish · 1 neutral · 6 bearish
Monthly
Bearish
2 bullish · 1 neutral · 4 bearish
Moving averages (daily)
| SMA 10 | 67.01 | Bullish |
| EMA 10 | 67.71 | Bullish |
| SMA 20 | 66.36 | Bullish |
| EMA 20 | 67.03 | Bullish |
| SMA 50 | 68.59 | Bullish |
| EMA 50 | 67.17 | Bullish |
| SMA 100 | 66.54 | Bullish |
| EMA 100 | 67.67 | Bullish |
| SMA 200 | 70.43 | Bearish |
| EMA 200 | 69.52 | Bullish |
Oscillators (daily)
| RSI (14) | 61.00 | Neutral |
| MACD (12, 26) | 0.44 | Bullish |
| Momentum (12) | 6.42 | Bullish |
| Stochastic %K (14) | 78.14 | Neutral |
| Williams %R (14) | -21.86 | Neutral |
| CCI (20) | 183.9 | Bearish |
Pivot points (classic, last session)
S3 67.04 | S2 68.24 | S1 68.91 | Pivot 70.11 | R1 70.78 | R2 71.98 | R3 72.65 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.14 USD
Yield on today's price
0.20%
Frequency
Quarterly
Next ex-dividend date
23 Oct 2026
| Ex-dividend date | Amount per share |
|---|---|
| 23 Oct 2026 (upcoming) | 0.0400 |
| 24 Jul 2026 | 0.0350 |
| 2 Apr 2026 | 0.0350 |
| 9 Jan 2026 | 0.0350 |
| 24 Oct 2025 | 0.0350 |
| 25 Jul 2025 | 0.0350 |
| 25 Apr 2025 | 0.0350 |
| 14 Jan 2025 | 0.0350 |
| 18 Oct 2024 | 0.0300 |
| 19 Jul 2024 | 0.0300 |
| 18 Apr 2024 | 0.0300 |
| 12 Jan 2024 | 0.0300 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
GEHC SEC filings
22 Sep 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
18 Aug 2026
8-KSEC EDGAR
Director or officer change
29 Jul 2026
8-KSEC EDGAR
Regulation FD disclosure
29 Jul 2026
10-QSEC EDGAR
Quarterly report
29 Jul 2026
8-KSEC EDGAR
Results of operations
23 Jul 2026
8-KSEC EDGAR
Results of operations; Director or officer change
11 May 2026
8-KSEC EDGAR
Shareholder vote results; Other events
29 Apr 2026
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.